Myriad Genetics Q4 2023 Adj EPS $0.04 Beats $0.01 Estimate, Sales $196.60M Beat $194.78M Estimate
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics (NASDAQ:MYGN) reported Q4 2023 adjusted EPS of $0.04, surpassing the $0.01 estimate, with sales of $196.60M exceeding the $194.78M forecast. This represents a 10.57% increase in sales compared to the same period last year.
February 27, 2024 | 9:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics reported a significant beat on both EPS and sales estimates for Q4 2023, with a notable year-over-year sales growth.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The substantial year-over-year sales growth further strengthens the case for a positive outlook on MYGN's stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100